Seinfeld v. Hospital Corp. of America

685 F. Supp. 1057, 1988 U.S. Dist. LEXIS 3955, 1988 WL 47183
CourtDistrict Court, N.D. Illinois
DecidedMay 2, 1988
Docket85 C 6651
StatusPublished
Cited by9 cases

This text of 685 F. Supp. 1057 (Seinfeld v. Hospital Corp. of America) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Seinfeld v. Hospital Corp. of America, 685 F. Supp. 1057, 1988 U.S. Dist. LEXIS 3955, 1988 WL 47183 (N.D. Ill. 1988).

Opinion

MEMORANDUM OPINION

BRIAN BARNETT DUFF, District Judge.

This case arises under § 16(b) of the Securities Exchange Act of 1934 (“§ 16(b)”), 15 U.S.C. § 78p(b). Defendant Hospital Corporation of America (“HCA”) and nominal defendant American Hospital Supply Corporation (“American”) have each moved to dismiss pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. For the reasons set forth below, the motions are granted.

FACTS 1

In late 1984, the chief executives of HCA, an operator of medical facilities, and American, a manufacturer and distributor of health care products, began discussing the possibility of a merger in response to adverse business conditions in their related industries. On March 30, 1985, the companies executed an Agreement and Plan of Reorganization (the “Merger Agreement”) in contemplation of a merger.

Under the Merger Agreement, the merger would involve an exchange of stock whereby the shareholders of each company would receive stock in a third, newly-created company. During the period prior to either the effectuation of the merger (“Merger Date”) or other termination of the Merger Agreement (“Termination Date”), both parties were to have a number of special rights against and obligations to the other, including the right of access to confidential financial information and the obligation to keep their businesses intact and to report any material changes therein.

The Merger Agreement also included a provision to defend against a third party interfering in the consolidation and merger. This provision — the so-called “lock-up” option 2 — gave both companies the option to effect an exchange of 39 million newly issued American shares, representing 35% of that company’s stock, for 29.5 million shares of HCA stock, a 25% stake, should a third party make a public competing offer for American common stock. The option also provided that, in the event of its exercise, both companies would vote the shares acquired under it (the “option shares”) in favor of the Merger Agreement and against any competing offerors.

On June 20, 1985, nearly three months after the Merger Agreement was executed, Baxter Travenol Laboratories, Inc. (“Baxter”), a manufacturer of a diverse line of medical care products, announced a proposal to acquire American at a price 45% higher than the effective price offered by HCA. The American Board rejected the offer.

On June 24, HCA informed American that the Baxter offer activated the lock-up option, and on July 2, upon expiration of the applicable statutory waiting period, the option became exercisable by either American or HCA.

On July 12, HCA filed a Form 3 with the Securities and Exchange Commission (“SEC”) in which it reported that on July 2, by virtue of the lock-up option, it had become the “beneficial owner” of 39 million shares of American common stock for the purposes of § 16(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78p(a).

Baxter subsequently sweetened its offer for American, and on July 15, 1985, these two companies announced the completion of a merger agreement between them. On that same date, Baxter, American, and HCA entered into an agreement (the “Settlement Agreement”) in which HCA agreed to the termination of the Merger Agreement and the relinquishment of the “lockup” option in return for the payment of *1059 cash by American. HCA was to receive $10 million if the Baxter-American merger was not consummated by April 1, 1986, $150 million if it was so consummated, and an additional $50 million if, following consummation but prior to January 15, 1991, HCA and its customers had purchased a specified amount of Baxter products. On July 19, 1985, HCA reported to the SEC that it was no longer a “beneficial owner” of American.

Plaintiff did not make a demand on American to file suit against HCA. Instead, believing that such a demand would be futile, he filed this action alleging that HCA’s relinquishment of its rights under the lock-up option in exchange for $200 million constituted insider trading under § 16(b) and that, accordingly, HCA must disgorge all sums received pursuant to the Settlement Agreement. Plaintiff also named American as a nominal defendant in the action.

HCA and American filed separate motions to dismiss under Fed.R.Civ.P.Rule 12(b)(6). HCA claims that plaintiff failed to state a claim under § 16(b) for two reasons: (1) HCA was never a beneficial owner for the purposes of § 16(b); (2) even if HCA did become a beneficial owner when the lock-up option became exercisable, it did not thereafter effectuate a “purchase and sale” of American equity securities as required for liability to arise under § 16(b).

American adopts HCA’s grounds for moving to dismiss. It also moves to dismiss on the grounds that plaintiff lacks standing because he failed to first demand that American bring this action, and cannot establish that such a demand would have been futile.

DISCUSSION

Standing

Section 16(b) provides that the owner of shares of a corporation may bring a § 16(b) suit on behalf of the corporation, provided that he first makes a demand of the corporation to institute the suit and the corporation fails to do so. 3 Section 16(b), Securities Exchange Act of 1934, 15 U.S.C. § 78p(b). Courts, however, have analogized this provision to Federal Rule of Civil Procedure Rule 23.1, see Colan v. Monumental Corp., 524 F.Supp. 1023, 1028 (N.D.Ill.1981); Abbe v. Goss, 411 F.Supp. 923 (S.D.N.Y.1975), and have therefore excused plaintiffs for failing to make such a demand “where the complaint recites circumstances which would make the demand futile or useless.” Jannes v. Microwave Communications, Inc., 57 F.R.D. 18, 21 (N.D.Ill.1972). “[T]he determination of whether a demand is necessary or whether an excuse is sufficient is within the sound discretion of the [district] court.” Id. See also Nussbacher v. Continental Illinois National Bank & Trust, 518 F.2d 873, 877 (7th Cir.1975), cert. denied, 424 U.S. 928, 96 S.Ct. 1142, 47 L.Ed.2d 338 (1976); Prager v. Sylvestri, 449 F.Supp. 425 (S.D.N.Y. 1978).

Plaintiff acknowledges that he never made a demand upon American to bring an action against HCA, but claims that his complaint sets forth facts indicating that such a demand would have been futile. This court agrees. Unlike most § 16(b) actions, in which the group of alleged insiders is composed of a small number of the corporation’s officers and directors, in this case each and every American board member took part in the deal with HCA.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
685 F. Supp. 1057, 1988 U.S. Dist. LEXIS 3955, 1988 WL 47183, Counsel Stack Legal Research, https://law.counselstack.com/opinion/seinfeld-v-hospital-corp-of-america-ilnd-1988.